.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has actually chosen Eli Lilly (NYSE: LLY) as its best biopharma pick for 2025 as well as rated an additional nine labels in the room as obese. The investment banking company claimed in a note that it continues to strongly believe “diabesity is actually set to come to be.